{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:05:08Z","timestamp":1773806708422,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1038\/sj.bjc.6601463","type":"journal-article","created":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T18:31:12Z","timestamp":1073413872000},"page":"65-69","source":"Crossref","is-referenced-by-count":47,"title":["Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma"],"prefix":"10.1038","volume":"90","author":[{"given":"M","family":"Mabed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"El-Helw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Shamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,1,6]]},"reference":[{"key":"BF6601463_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000226413","volume":"43","author":"H Becker","year":"1986","unstructured":"Becker H (1986) Botany of European mistletoe (Viscum album L.). Oncology 43: 2\u20137","journal-title":"Oncology"},{"key":"BF6601463_CR2","first-page":"73","volume":"25","author":"J Beuth","year":"1993","unstructured":"Beuth J, KO HL, Tungal L, Steuer MK, Geisel J, Jeljaszewics J, Pulverer G (1993) Das lektin der mistel als immunomodulatoe in der adjuvanten tumortherapie. Detsche zeitschrift fur onkologie 25(3): 73\u201376","journal-title":"Detsche zeitschrift fur onkologie"},{"key":"BF6601463_CR3","unstructured":"Bosch FX, Munoz N (1991) Hepatocellular carcinoma in the world: epidemiologic questions in etiology, pathology and treatment of hepatocellular carcinoma in North America. In: Tabor E, DiBisecglie AM, Purcell RH, (eds) Advances in the Applied Biotechnology Series, pp 35\u201354"},{"key":"BF6601463_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/bjc.1998.438","volume":"78","author":"Y Chao","year":"1998","unstructured":"Chao Y, Chan WK, Birkhofer MJ, Hu OPY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY, Lee SD (1998) Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma. Br J Cancer 78(1): 34\u201339","journal-title":"Br J Cancer"},{"key":"BF6601463_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.1986.4.2.244","volume":"4","author":"DL Dexter","year":"1986","unstructured":"Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4: 244\u2013257","journal-title":"J Clin Oncol"},{"key":"BF6601463_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000227434","volume":"52","author":"G Falkson","year":"1995","unstructured":"Falkson G, Burger W (1995) A phase II trial of Vindesine in hepatocellular carcinoma. Oncology 52: 86\u201387","journal-title":"Oncology"},{"key":"BF6601463_CR7","first-page":"3322","volume":"50","author":"T Hajto","year":"1990","unstructured":"Hajto T, Hostanska K, Frel K, Rohrdorf C, Gabius HJ (1990) Increased secretion of tumor necrosis factor-\u03b1, interleukin-1, and interleukin-6 by human mononuclear cells exposed to B\u2013galactosid\u2013specific lectin from clinically applied mistletoe extract. Cancer Research 50: 3322\u20133326","journal-title":"Cancer Research"},{"key":"BF6601463_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0192-0561(87)90095-6","volume":"9","author":"K Hamprecht","year":"1987","unstructured":"Hamprecht K, Handgretinger R, Voetsch W, Anderer FA (1987) Mediation of human NK-activity by components in extracts of viscum album. Int J Immunopharmacol 9: 199\u2013209","journal-title":"Int J Immunopharmacol"},{"key":"BF6601463_CR9","volume-title":"A vesicle fraction of mistletoe induces T cell proliferation of sensitized lymphocytes in patients treated with mistletoe extracts","author":"S Hartmann","year":"1995","unstructured":"Hartmann S, Scheffler A, Lessmann M (1995) A vesicle fraction of mistletoe induces T cell proliferation of sensitized lymphocytes in patients treated with mistletoe extracts. Beitrag Zur Tagung Der Immunologischen Gesellschaft: Regensburg"},{"key":"BF6601463_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jnci\/84.4.262","volume":"84","author":"C Huang","year":"1992","unstructured":"Huang C, Wu M, Xu G, LiDZ, Cheng H, Tu ZX, Jiang HO, Gu JR (1992) Overexpression of the MDRI gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84: 262\u2013264","journal-title":"J Natl Cancer Inst"},{"key":"BF6601463_CR11","first-page":"1221","volume":"43","author":"O Janssen","year":"1993","unstructured":"Janssen O, Scheffler A, Kabelitz D (1993) In vitro effects of mistletoe extracts and mistletoe lectins: Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittel Forschung, Drug\u2013Research 43(11): 1221\u20131227","journal-title":"Arzneimittel Forschung, Drug\u2013Research"},{"key":"BF6601463_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EM Kaplan","year":"1959","unstructured":"Kaplan EM, Meier P (1959) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"BF6601463_CR13","first-page":"109","volume":"8","author":"GS Kienle","year":"2003","unstructured":"Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H (2003) Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8(3): 109\u2013119","journal-title":"Eur J Med Res"},{"key":"BF6601463_CR14","unstructured":"Koehler R (1992) Verfahren und vorrichtung zur herstellung wassriger kolloide. Europaisches Patent Nr. 0310984"},{"key":"BF6601463_CR15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/1097-0142(19901015)66:8<1685::AID-CNCR2820660805>3.0.CO;2-W","volume":"66","author":"ECS Lai","year":"1990","unstructured":"Lai ECS, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES, Wong J (1990) Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 66: 1685\u20131687","journal-title":"Cancer"},{"key":"BF6601463_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","volume":"62","author":"CI Lai","year":"1988","unstructured":"Lai CI, Wu PC, Chan GCB, Lok ASF, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer 62: 479\u2013483","journal-title":"Cancer"},{"key":"BF6601463_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/BF02145845","volume":"27","author":"PG Lankish","year":"1978","unstructured":"Lankish PG, Vogt W (1978) Potentiation of hemolysis by the combined action of phospholipase A and a basic peptide containing s-s bonds (viscotoxin B). Experientia 27(2): 122\u2013123","journal-title":"Experientia"},{"key":"BF6601463_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/BF01656375","volume":"6","author":"NW Lee","year":"1982","unstructured":"Lee NW, Wong J, Ong GB (1982) The surgical management of primary carcinoma of the liver. World J Surg 6: 66\u201375","journal-title":"World J Surg"},{"key":"BF6601463_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/BF00685682","volume":"31","author":"J Lin","year":"1993","unstructured":"Lin J, Shiu W, Leung WT, Tao M, Leung N, Lau WY, Li AK (1993) Phase II study of high dose Ifosfamide in hepatocellular carcinoma. Cancer Chemotherapy Pharmacol 31: 338\u2013339","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"BF6601463_CR20","first-page":"883","volume-title":"Cancer: principles and practice of oncology","author":"MT Lotze","year":"1993","unstructured":"Lotze MT, Flickinger JC, Carr BJ (1993) Hepatobiliary system. In: DeVita VT, Hellman S, Rosenberg SA, (eds) Cancer: principles and practice of oncology, ed 4. pp 883\u2013914. Philadelphia: J.B. Lippincott"},{"key":"BF6601463_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-71257-9","volume-title":"Die Mistel","author":"P Luther","year":"1987","unstructured":"Luther P, Becker H (1987) Die Mistel. Berlin: Spring Verlag"},{"key":"BF6601463_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Ataquet M (1981) Reporting results of cancer treatment. Cancer 47: 207\u2013214","journal-title":"Cancer"},{"key":"BF6601463_CR23","first-page":"3646","volume":"50","author":"EA Mueller","year":"1990","unstructured":"Mueller EA, Anderer FA (1990) Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokin\u2013activated killer cells: chemical specificity of target cell recognition. Cancer Research 50: 3646\u20133651","journal-title":"Cancer Research"},{"key":"BF6601463_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0162-3109(89)90003-9","volume":"17","author":"EA Mueller","year":"1989","unstructured":"Mueller EA, Hamprecht K, Anderer FA (1989) Biochemical characterization of a component in extracts of viscum album enhancing human NK cytotoxicity. Immunopharmacology 17: 11\u201318","journal-title":"Immunopharmacology"},{"key":"BF6601463_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000227142","volume":"50","author":"S Okada","year":"1993","unstructured":"Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K (1993) A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50: 22\u201326","journal-title":"Oncology"},{"key":"BF6601463_CR26","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/1097-0142(19800515)45:10<2663::AID-CNCR2820451030>3.0.CO;2-G","volume":"45","author":"K Okuda","year":"1980","unstructured":"Okuda K (1980) Primary liver cancer in Japan. Cancer (Phila.) 45: 2663\u20132672","journal-title":"Cancer (Phila.)"},{"key":"BF6601463_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","volume":"56","author":"K Okuda","year":"1985","unstructured":"Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer (phila.) 56: 918\u2013928","journal-title":"Cancer (phila.)"},{"key":"BF6601463_CR28","first-page":"1026","volume":"267","author":"E O'Reilly","year":"1998","unstructured":"O'Reilly E, Stuart K, Kemeny N, Steger C, Raeburn I, Sanz-Altamira P (1998) A phase II trial of irinotecan (CPT-II) in patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 267: 1026","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601463_CR29","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/BF01955552","volume":"42","author":"G Ribereau\u2013Gayon","year":"1986","unstructured":"Ribereau\u2013Gayon G, Jung ML, Baudino S, Salle JP (1986) Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells. Experientia 42: 594\u2013599","journal-title":"Experientia"},{"key":"BF6601463_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1023\/A:1008249328792","volume":"8","author":"P Rougier","year":"1997","unstructured":"Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Ednis A, Seymour L (1997) A phase II study of raltitrexed (Tomudex) in patients with hepatocellular carcinoma. Ann Oncol 8: 500\u2013502","journal-title":"Ann Oncol"},{"key":"BF6601463_CR31","first-page":"139","volume-title":"Grundlagen der Misteltherapie","author":"R Scheer","year":"1996","unstructured":"Scheer R (1996) Sicherung der pharmazeutischen Qualitat von mistelpraparaten. In: R. Scheer, H. Becker, PA Berg (Ed) Grundlagen der Misteltherapie, pp 139\u2013150. Stuttgart: Hippokrates Verlage"},{"key":"BF6601463_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1104\/pp.101.3.745","volume":"101","author":"G Schrader-Fischer","year":"1993","unstructured":"Schrader-Fischer G, Apel K (1993) The anticyclic timing of leaf senescence in the parasitic plant viscum album is closely correlated with the selective degradation of sulfur-rich viscotoxin. Plant physiology 101: 745\u2013749","journal-title":"Plant physiology"},{"key":"BF6601463_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/BF01647413","volume":"69","author":"JL Schultze","year":"1991","unstructured":"Schultze JL, Stettin A, Berg PA (1991) Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.). Klinische wochenschrift 69: 397\u2013403","journal-title":"Klinische wochenschrift"},{"key":"BF6601463_CR34","unstructured":"Steiner R (1961) Vortrag vom 2. 4. 1920; Geisteswissenschaft und Medizin GA 312, pp 246\u2013262. Dornach: Verlag der Rudolf Steiner NachlaBverwaltung"},{"key":"BF6601463_CR35","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<410::AID-CNCR8>3.0.CO;2-P","volume":"86","author":"K Stuart","year":"1999","unstructured":"Stuart K, Tessitore J, Rudy J, Clendennin N, Johnston A (1999) A phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 86: 410\u2013414","journal-title":"Cancer"},{"key":"BF6601463_CR36","first-page":"111","volume-title":"Grundlagen der mistletherapie","author":"K Urech","year":"1996","unstructured":"Urech K, Schaller G, Giannattasio M (1996) Bioassay zur bestmmung von viscotoxinen. In: Scheer R, Becker H, Berg PA (eds) Grundlagen der mistletherapie, pp 111\u2013118. Stutgart: Hippokrates Verlag"},{"key":"BF6601463_CR37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.1994.12.6.1323","volume":"12","author":"AP Venook","year":"1994","unstructured":"Venook AP (1994) Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 12: 1232\u20131234","journal-title":"J Clin Oncol"},{"key":"BF6601463_CR38","first-page":"1937","volume":"45","author":"J Whang-Peng","year":"1998","unstructured":"Whang-Peng J, Chao Y (1998) Clinical trials of hepatocellular carcinoma in Taiwan. Hepatogastroenterology 45(24): 1937\u20131943","journal-title":"Hepatogastroenterology"},{"key":"BF6601463_CR39","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/oxfordjournals.annonc.a058882","volume":"5","author":"R Wierzbicki","year":"1994","unstructured":"Wierzbicki R, Ezzat A, Abdel-Warith A, Ayoub A, Kagevi I, Fadda M, Siech J, Abdul Kareem M, Amin T, Yazigi A (1994) Phase II trial of chronic daily VP 16 administration in unresectable hepatocellular carcinoma (HCC). Ann Oncol 5: 466\u2013467","journal-title":"Ann Oncol"},{"key":"BF6601463_CR40","unstructured":"World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO Offset Publications"},{"key":"BF6601463_CR41","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/0277-5379(88)90104-6","volume":"24","author":"T Yoshida","year":"1988","unstructured":"Yoshida T, Okazaki N, Yoshino M, Ohkura H, Miyamoto K, Shimado Y (1988) Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol 24: 1897\u20131898","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF6601463_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/108497801750096041","volume":"16","author":"N Zarkovic","year":"2001","unstructured":"Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, Borovic S, Cipak A, Sabolovic S, Konitzer M, Mang S (2001) An overview on anticancer activities of the vsicum album extract Isorel. Cancer Biother Radiopharm 16: 55\u201362","journal-title":"Cancer Biother Radiopharm"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601463","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:54:36Z","timestamp":1684414476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["BF6601463"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601463","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}